MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ
5.70
-0.15
-2.56%
Pre Market: 5.80 +0.1 +1.75% 08:22 05/14 EDT
OPEN
5.82
PREV CLOSE
5.85
HIGH
5.90
LOW
5.66
VOLUME
839
TURNOVER
10.90K
52 WEEK HIGH
23.43
52 WEEK LOW
2.900
MARKET CAP
39.11M
P/E (TTM)
-0.7924
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PSTV last week (0504-0508)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Charles River Labs (CRL)
TipRanks · 5d ago
Plus Therapeutics Presents Plenary Session Reviewing Key Clinical And Translational Data, Including Phase 1 ReSPECT-LM Trial Of REYOBIQ At 2026 AANS Annual Scientific Meeting
Benzinga · 6d ago
Plus Therapeutics highlights Phase 1 ReSPECT-LM REYOBIQ data in AANS plenary session
PUBT · 6d ago
PLUS THERAPEUTICS ANNOUNCES ORAL PRESENTATION HIGHLIGHTING REYOBIQ™ CLINICAL AND TRANSLATIONAL DATA DEMONSTRATING FAVORABLE SAFETY, SURVIVAL, AND EMERGING IMMUNOMODULATION IN LEPTOMENINGEAL METASTASES
Reuters · 6d ago
Plus Therapeutics unit wins Medicare enrollment approval for CNSide diagnostic lab
PUBT · 05/07 11:35
Plus Therapeutics unit CNSide Diagnostics wins Medicare enrollment for CNSide CSF assay platform
PUBT · 05/07 11:34
Plus Therapeutics Subsidiary Gets Enrolled In Medicare Program, Receives Provider Transaction Access Number From Centers For Medicare & Medicaid Services
Benzinga · 05/07 11:33
More
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Webull offers Plus Therapeutics Inc (USA) stock information, including NASDAQ: PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.